VCT220

DRUG4 trials

Sponsors

Vincentage Pharma Co., Ltd

Conditions

ObesityObesity & OverweightObesity, OverweightOverweight

Phase 1

A Pharmacokinetic Study of VCT220 in Particicants With Hepatic Injury and Normal Hepatic Function

CompletedNCT06938529

Vincentage Pharma Co., LtdObesity, Overweight

Start: 2025-04-18End: 2025-07-25Updated: 2025-08-14

A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients

CompletedNCT07347808

Vincentage Pharma Co., LtdObesity & Overweight

Start: 2025-12-25End: 2026-02-18Updated: 2026-03-27

Phase 2

A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

CompletedNCT06569355

Vincentage Pharma Co., LtdObesity, Overweight

Start: 2023-12-27End: 2024-08-01Updated: 2025-07-01

Phase 3

A Research Study of VCT220 in Adult Chinese Participants With Obesity

CompletedNCT06939296

Vincentage Pharma Co., LtdObesity, Overweight

Start: 2024-12-24End: 2026-03-31Updated: 2026-09-16

Related Papers

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial

Signal Transduction and Targeted Therapy2026-08-14